^
BIOMARKER:

FGFR2 mutation

i
Other names: FGFR2, BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25, Fibroblast growth factor receptor 2
Entrez ID:
FGFR2 mutation
Urothelial Cancer
erdafitinib
Sensitive: A1 - Approval
FGFR2 mutation
Cholangiocarcinoma
erdafitinib
Sensitive: C1 - Off-label
FGFR2 mutation
Gastric Cancer
erdafitinib
Sensitive: C1 - Off-label
FGFR2 mutation
Cholangiocarcinoma
infigratinib
Sensitive: C2 – Inclusion Criteria
FGFR2 mutation
Cholangiocarcinoma
ARQ 087
Sensitive: C2 – Inclusion Criteria
FGFR2 mutation
Cholangiocarcinoma
TAS 120
Sensitive: C2 – Inclusion Criteria
FGFR2 mutation
Cholangiocarcinoma
TT-00420
Sensitive: C2 – Inclusion Criteria
FGFR2 mutation
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
FGFR2 mutation
NSCLC
nintedanib
Sensitive: C3 – Early Trials
FGFR2 mutation
Cholangiocarcinoma
pemigatinib
Sensitive: C3 – Early Trials
FGFR2 mutation
Cholangiocarcinoma
FGFR2 inhibitor
Resistant: C3 – Early Trials
FGFR2 mutation
Cholangiocarcinoma
Debio 1347
Sensitive: C3 – Early Trials
FGFR2 mutation
Solid Tumor
CPL304110
Sensitive: D – Preclinical
FGFR2 mutation
Multiple Myeloma
infigratinib
Sensitive: D – Preclinical
FGFR2 mutation
Endometrial Cancer
infigratinib
Sensitive: D – Preclinical
FGFR2 mutation
Endometrial Cancer
PD 0173074
Sensitive: D – Preclinical
FGFR2 mutation
Endometrial Cancer
TKI258
Sensitive: D – Preclinical
FGFR2 mutation
Estrogen Receptor Positive Breast Cancer
fulvestrant
Resistant: D – Preclinical
FGFR2 mutation
Estrogen Receptor Positive Breast Cancer
palbociclib
Resistant: D – Preclinical